JP4634757B2 - Emulsified liquid enteral nutrient - Google Patents

Description

  The present invention is used for nutritional management of children, elderly people, and patients before and after surgery who cannot take a normal meal, and can be easily and stably supplied to the digestive organs such as the stomach and intestine by oral and gavage. The present invention relates to an emulsified liquid enteral nutrient that can be expected to improve the quality, prevent the occurrence of sores and cure.

  Conventionally, oral feeding or enteral feeding by tube is mainly employed for patient nutrition before and after surgery. Enteral nutrition is a natural nutritional method because it uses the stomach and intestines, and is difficult to cause deterioration of the function of the digestive tract.

  Nutrients (enteral nutrients) used for enteral nutritional supplements contain a sufficient amount of various nutrients (sugars, proteins, fats, minerals, vitamins, water, etc.) that are necessary for the body. In addition to patients who have difficulty in swallowing food, they are widely used as nutritional foods to supplement the nutrition required for elderly people such as bedridden elderly people.

  Furthermore, in recent years, prescriptions for enteral nutrients that actively add active ingredients that can be expected to treat and prevent diseases in addition to nutritional supplements have been studied. According to the Basic Life Survey, the highest complaint rate is 92.5% for back pain, 91.0% for shoulder stiffness, 53.8% for joint pain, and 33.8% for joint pain. It accounts for 50% of all chronic diseases, and many elderly patients suffer from diseases such as low back pain and joint pain. Also, many bedridden patients suffer from skin diseases such as sores. Therefore, enteral nutrients that are expected to have effects such as improvement of joint pain, prevention of occurrence of wounds, and healing at the same time as sufficient nutritional supplementation are desired.

  On the other hand, chitin and chitosan are said to be animal fibers, and plant fibers are negative ions, while chitin and chitosan are positive ions, and are thought to be closely related to the excellent efficacy of chitin and chitosan. For these reasons, chitin / chitosan is not an essential nutrient, but has attracted attention as a seventh nutrient necessary for health. The effects of chitin and chitosan are as follows: 1) Suppression of blood cholesterol and neutral fat elevation, 2) Strengthening of liver function, 3) Improvement of diabetes, 4) Suppression of increase in blood glucose level, 5) Hypotension against hypertension, 6 ) Immunostimulation, 7) suppression against tumors, 8) improvement of joint pain, 9) promotion of skin regeneration and the like.

  The chitin / chitosan hydrolyzate has also been reported to have the same effect as chitin / chitosan. For example, Patent Document 1 listed below relates to a health food having a joint pain alleviating / ameliorating action, including glucosamine, cat's claw, etc. Patent Document 2 below discloses a composition based on chondroitin sulfate and chitosan and a dietary supplement for preventing or treating rheumatic disorders and the like by general administration.

  In the recent market, many health foods containing chitin / chitosan-related substances are available in the form of soft capsules, tablets, granules and the like.

Furthermore, Tsujimoto et al. Reported on the therapeutic effect of milk containing natural N-acetylglucosamine on knee osteoarthritis. (See Non-Patent Document 1)
JP 2003-155250 A JP 2002-539233 A New drugs and Linyi J.New Rem. & Clin.Vol.52, No.3, 2003, p71-82,

  In general, enteral nutrients are required to have stability that can withstand storage at room temperature for several months, fluidity of the tube that can pass through a thin tube in a short time, etc. It is preferable that there are few things. As described above, chitin / chitosan can sufficiently be expected to have effects such as improvement of joint pain, prevention of wound formation and healing.

  Therefore, the object of the present invention can be expected to have effects such as improvement of joint pain, prevention of wound formation and healing, as well as sufficient nutritional supplementation. The object is to provide an enteral nutrient capable of stably supplying a nutrient solution.

The present inventors focused on the effects of improvement of joint pain possessed by chitin and chitosan, prevention of occurrence of sores and healing, etc., and as a result of intensive studies to use these as enteral nutrients, It has been found that enteric nutrients having excellent emulsification stability and tube fluidity can be obtained by using chitin hydrolysates and using them as emulsions, and the present invention has been completed.

That is, the present invention is mainly composed of (A) a chitin hydrolyzate containing at least N-acetylglucosamine , (B) a protein and / or a decomposition product thereof, (C) a lipid, (D) a saccharide, and (E) an emulsifier. And the total calorie is 70 to 200 kcal / 100 ml, and the total liquid mass is 0.01 to 0.5 mass% , the (B) is 2.0 to 10.0 mass%, The emulsified liquid enteral nutrient containing 1.0 to 10.0% by mass of (C), 10 to 30% by mass of (D), and 0.05 to 1.0% by mass of (E). It is characterized by that.

According to the present invention, by making the enteral nutrient into an emulsified liquid, various substances such as proteins and lipids necessary as nutrients can be homogenized and administered. And it can be made excellent in emulsification stability and tube fluidity by containing 0.01-0.5 mass% of chitin hydrolyzate containing at least N-acetylglucosamine with respect to the total liquid mass. Furthermore, the bioactive effect of the chitin hydrolyzate can also be expected to improve joint pain, prevent the occurrence of wounds, and have a therapeutic effect. And because it can take a sufficient amount of various nutrients necessary for the body in a well-balanced manner, it can be used as an alternative to meals for patients and elderly people who cannot take a normal meal and maintain good nutrition. I can do it.

The arbitrariness preferred that chitin hydrolyzate chitin hydrolyzate is 1-8 N- acetylglucosamine molecules bound. The chitin hydrolyzate may be N-acetylglucosamine. According to this, it can be set as the enteral nutrient which was more excellent in emulsion stability.

By an emulsified liquid enteral nutrient containing at least chitin hydrolyzate N- acetylglucosamine, emulsion stability is high, the stomach oral and tube, and simple and stable in the digestive organs such as enteral It can be set as the enteral nutrient which can supply a liquid. Further, the physiologically active effects possessed by chitin hydrolyzate, improving therapeutic agent of joint pain, effect of the prevention and healing agents such bedsore can be expected.

  In the present invention, the enteral nutrient is a nutrient that is enterally administered by the oral administration method or the tube administration method, and typical enteral nutrients include liquid foods, It is a nutrient used as a means for supplying necessary nutrients to patients who cannot be ingested and elderly people such as bedridden elderly people.

  And, in order to take these nutrients such as proteins, lipids and carbohydrates at the same time in a well-balanced manner, it is preferably prepared in an emulsified liquid. The enteral nutrient of the present invention is an emulsified liquid enteral nutrient It is.

The a N- acetylglucosamine used in the present invention chitin hydrolyzate containing at least, crab, chemically or biochemically hydrolyzed to chitin by a conventional method, which is prepared by conventional methods from the shells of crustaceans such as shrimp It can be obtained by decomposing and fractionating as necessary.

A chitin hydrolyzate containing at least N-acetylglucosamine can be obtained by, for example, treating crustacean crusts such as shrimp, crabs, krill, etc. by acid treatment to remove calcium, and sodium hydroxide treatment to remove proteins. The chitin obtained from the obtained chitin or other sources, preparation methods, etc. is used as a raw material, and acid such as hydrochloric acid, formic acid, acetic acid, sulfuric acid is added to partially hydrolyze chitin, and then neutralized with alkali It can be produced by a salting method. The chitin hydrolyzate thus obtained is generally a mixture having a relatively wide molecular weight distribution, and is a mixture in which about 1 to 30 N-acetylglucosamine molecules are bound.

The chitin hydrolyzate containing at least N-acetylglucosamine used in the present invention is preferably one in which 1 to 30 N-acetylglucosamine molecules are bonded, more preferably 1 to 8 bonded. Moreover, N-acetylglucosamine may be sufficient.

In the present invention, the chitin hydrolyzate can be used as a hydrolyzate having a predetermined degree of polymerization by a method such as column chromatography or solvent fractionation. It is more advantageous in terms of cost.

The chitin hydrolyzate may be a free form or may form a salt. Examples of the salt include hydrochloride, sulfate and the like.

As these hydrolysates and salts thereof, commercially available products can be used. Specifically, these hydrolysates and their salts are decomposed products in which 1 to 6 N-acetylglucosamine molecules are bonded (trade name; “NA-COS-”). Y "Yaizu Suisankagaku Industry, Ltd. Co., Ltd.), etc. can be mentioned.

The emulsified liquid enteral nutrient of the present invention, the chitin hydrolyzate from the viewpoint of the effect expression on their physical properties, containing 0.01 to 0.5% by weight, based on the total liquid weight, preferably 0. Contains 0.5 to 0.2 mass%.

If the content of the chitin hydrolyzate is 0.01% by mass or less, the emulsification stability and the tube fluidity cannot be improved, and if it is 0.5% by mass or more, the protein may aggregate. Therefore, it is not preferable.

  In addition, the emulsified liquid enteral nutrient of the present invention contains protein, lipid, and sugar as main components and is well-balanced under a nutritional design in order to sufficiently supply the nutrients necessary for the human body. The

Protein and / or degradation product thereof, the total liquid volume, 2.0-10.0% by mass is, more preferably 3.5-6.0 wt%. If the protein and / or its degradation product is 2.0% by mass or less, it is difficult to obtain the required amount of protein, and if it is 10.0% by mass or more, the protein may be aggregated, which is not preferable.

Further, lipids, the total liquid volume, 1.0 to 10.0% by mass is, more preferably from 2.0 to 8.0 wt%. If the lipid is 1.0% by mass or less, it is difficult to obtain a necessary amount of lipid, and if it is 10.0% by mass or more, the balance with other nutrients is deteriorated.

Further, carbohydrate, the total liquid volume, from 10.0 to 30% by mass is, more preferably 15.0 to 25.0 wt%. If the saccharide is 10.0% by mass or less, it is difficult to obtain a necessary amount of saccharide, and if it is 30% by mass or more, the balance with other nutrients is deteriorated.

Then, the total calories of the enteral nutrient is a 70~200kcal / 100ml, more preferably 100~150kcal / 100ml. If the total calorie is 70 kcal / 100 ml or less, it is difficult to obtain a necessary amount of calories, and if it is 200 kcal / 100 ml or more, the viscosity of the emulsion becomes unpreferable.

  Proteins and / or degradation products thereof used in the present invention include, for example, casein or casein salts such as sodium caseinate and calcium caseinate, animal proteins such as milk protein, egg protein, fish protein, meat protein, and plants such as soybean protein. Sex proteins and their degradation products, amino acids and the like. These may use only 1 type and may use it in combination of 2 or more type. In addition, when a collagen peptide is used in combination, additional effects can be expected in improving arthropathy, preventing the occurrence of wounds and healing.

  The collagen peptide is preferably a fish-derived collagen peptide from the viewpoint of safety and hygiene. Collagen peptides derived from fish include, Neutral protease, alkaline protease, acidic protease, or enzyme preparation containing them by extracting collagen from fish selected from, puffer fish, yellowtail, scorpionfish, sea bream, etc. by adding water and extracting by heating or pressure heating extraction Peptide by treating with proteolytic enzymes such as Thereafter, it is obtained by concentrating and purifying the enzyme-treated product with a reverse osmosis membrane.

  The lipid used in the present invention includes, for example, soybean oil, corn oil, rapeseed oil, palm oil, safflower oil, sesame oil, perilla oil, palm oil and other vegetable oils, lard, beef tallow and other animal oils, fish oil, medium Examples include chain fatty acid triglycerides and other synthetic triglycerides, and further processed oils and fats thereof. These may be used alone or in combination of two or more.

  Fatty acids that constitute lipids include saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids. The polyunsaturated fatty acids include ω3 polyunsaturated fatty acids and ω6 polyunsaturated fatty acids. There are types. For example, lipids that supply ω3 polyunsaturated fatty acids include perilla oil and fish oil, and lipids that supply ω6 polyunsaturated fatty acids include corn oil, rapeseed oil, soybean oil, sunflower oil, and the like. Examples include flower oil. Nutritionally, it is important to take these fatty acids in a balanced manner. Since it is difficult to obtain these fatty acids with a single lipid, it is preferable to use a combination of two or more lipids.

  Examples of the saccharide used in the present invention include monosaccharides such as glucose and fructose, disaccharides such as maltose and lactose, oligosaccharides and polysaccharides. Of these, maltodextrins, dextrins, oligosaccharides and the like are preferably used because of easy digestibility and appropriate osmotic pressure. These may be used alone or in combination of two or more.

  The enteral nutrient of the present invention uses water to form an emulsified liquid. Examples of water include those used for ordinary processed foods such as pure water, purified water, ion exchange water, and deep sea water. The emulsified liquid enteral nutrient of the present invention has a total calorie of 70 to 200 kcal / 100 ml, more preferably 100 to 150 kcal / 100 ml, and the amount of water added is appropriately adjusted so that the total calorie falls within the above range.

Further, in order to stabilize the emulsified liquid, you blended emulsifier. Examples of the emulsifier include soybean or egg yolk phospholipid, monoglyceride, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, polyglycerin fatty acid ester, monoglyceride derivatives such as succinic acid monoglyceride or citrate ester of monoglyceride, and the like. These emulsifiers may be used alone or in combination of two or more.

The content of the emulsifier is the total liquid volume, 0.05 to 1.0% by mass is, more preferably 0.2 to 0.7 mass%. When the content of the emulsifier is 0.05% by mass or less, the emulsification stability effect is hardly exhibited, and the effect is sufficiently exhibited in the range up to 1.0% by mass. is not.

  The emulsified liquid enteral nutrient of the present invention preferably further contains dietary fiber, vitamins and minerals in addition to the components other than those described above in order to sufficiently replenish the nutrition necessary for the human body.

  Examples of dietary fibers include cellulose, polydextrose, guar gum enzyme degradation products, indigestible polysaccharides, and the like. In addition, the types and blending amounts of vitamins and minerals can be appropriately determined according to the intake amount described in, for example, the 6th revised “Japanese nutritional requirement” (published by 1st publisher).

  Moreover, in order to make the emulsified liquid of enteral nutrients more stable, a stabilizer may be further blended in addition to the emulsifier.

  Examples of the stabilizer include salts such as phosphate salts such as sodium hexametaphosphate and disodium hydrogen phosphate, and citrate salts such as sodium citrate. These stabilizers may be used alone or in combination of two or more.

  The emulsified liquid enteral nutrient of the present invention can further contain a fragrance, a gelling agent, a natural flavoring agent, a pigment and the like as auxiliary materials. Also if necessary. Shark cartilage extract, bone marrow extract, green tea extract, soybean isoflavone, casein phosphopeptide, lactose, lactoferrin, lactoperoxidase, palatinose, xylitol and the like can be blended. These components can bring about a more preferable effect for the improvement of arthropathy, the prevention of the occurrence of wounds and the healing of the present invention.

  The emulsified liquid enteral nutrient of the present invention can be prepared according to a conventional method. For example, each component is weighed, dissolved in warm water at about 60 ° C., and further emulsified using a high-pressure homogenizer. The emulsified liquid can be filled and sealed in a pouch or soft bag, and sterilized for production. Alternatively, the emulsion can be manufactured by UHT sterilization and filling a paper pack.

  The viscosity of the emulsified liquid enteral nutrient of the present invention is preferably 20 CP or less, more preferably 15 CP or less. By setting the viscosity to 20 CP or less, the tube fluidity can be improved.

  And it is preferable that an average particle diameter is 0.4 micrometer or less, More preferably, it is 0.3 micrometer or less. By setting the average particle size to 0.4 μm or less, the tube fluidity can be improved.

  Here, the average particle size is the average value of the size of oil droplets and dispersed proteins present in the emulsion, for example, microscopic image analysis method, Coulter counter method, dynamic light scattering method, light diffraction method It can be measured by a method such as centrifugation.

  The thus obtained emulsified liquid enteral nutrient is one that does not cause aggregation or precipitation of components even when stored for a long period of time, and can be easily applied to digestive organs such as the stomach and intestine even with extremely thin tubes. A nutrient solution can be supplied stably.

The dosage of the emulsified liquid enteral nutrient of the present invention varies depending on conditions such as age, sex, weight, living conditions, etc., but generally 1,000 to 1,500 kcal can be ingested per person per day. An amount is preferred. If the dosage, the said chitin hydrolyzate per preferably 1 day 0.05～10.0G, more preferably will be able to ingest 0.2～4.5G, bioactive effect can be expected.

  Next, the present invention will be described in more detail with reference to examples and comparative examples. Hereinafter, “mass%” is a value relative to the mass of the whole liquid emulsified liquid enteral nutrient solution.

[Example 1]
Each component was weighed according to the formulation shown in Table 1. Then, in warm water of about 60 ° C., minerals, sodium caseinate, milk protein, collagen peptide (trade name; “Marine Matrix” manufactured by Yaizu Suisan Chemical Co., Ltd.), DE25 dextrin, DE11 dextrin, guar gum degradation product, A chitin hydrolyzate (trade name: “NA-COS-Y” manufactured by Yaizu Suisan Chemical Co., Ltd.), to which 1 to 6 N-acetylglucosamine molecules were bonded, was dissolved by stirring. Next, succinic acid monoglyceride was previously dissolved in the oil mixture of rapeseed oil and medium chain fat in this liquid, and the oil mixture was added with stirring to perform rough emulsification. Furthermore, vitamins and a fragrance | flavor were mixed and it was left to stand for 15 minutes, stirring. The crude emulsion was homogenized again at a homogeneous pressure of 50 MPa, UHT sterilized, and then homogenized at a homogeneous pressure of 50 MPa to obtain an emulsion. This emulsion was aseptically filled into a paper pack (200 ml) to obtain an emulsified liquid enteral nutrient. The minerals and vitamins used in the present invention have the compositions shown in Table 2.

[Example 2]
An emulsified liquid enteral nutrient was obtained according to Example 1 except that N-acetylglucosamine (trade name; “Marine Sweet” manufactured by Yaizu Suisan Chemical Co., Ltd.) was used as the chitin hydrolyzate.

[ Reference Example 3]
An emulsified liquid enteral nutrient was obtained according to Example 1 except that a chitin hydrolyzate having 4 to 30 N-acetylglucosamine molecules bonded thereto was used.

[ Reference Example 4]
Each component was weighed according to the formulation shown in Table 1. And, minerals, sodium caseinate, DE11 dextrin, DE25 dextrin, guar gum degradation product, and chitosan hydrolyzate with 2-5 glucosamine molecules bound to hot water of about 60 ° C. (trade name; “COS-YS” Yaizu) Fishery Chemical Industry Co., Ltd.) was dissolved with stirring. Next, rapeseed oil in which succinic acid monoglyceride was dissolved in advance was added to this liquid while stirring to effect rough emulsification. Furthermore, vitamins and flavors were mixed and left for 15 minutes with stirring. This crude emulsion was homogenized twice at a homogeneous pressure of 15 MPa and a homogeneous pressure of 50 MPa to obtain an emulsion. Each 200 ml of this emulsified liquid was filled in a pouch and sterilized by retort at 123 ° C. for 8 minutes to obtain an emulsified liquid enteral nutrient. The same minerals and vitamins as in Example 1 were used.

[ Reference Example 5]
An emulsified liquid enteral nutrient was obtained according to Reference Example 4 except that glucosamine (trade name; “natural glucosamine” manufactured by Yaizu Suisan Chemical Co., Ltd.) was used as the chitosan hydrolyzate.

[ Reference Example 6]
An emulsified liquid enteral nutrient was obtained according to Reference Example 4 except that a hydrolyzate having 4 to 30 glucosamine molecules was used as the chitosan hydrolyzate.

[Example 7]
Each component was weighed according to the formulation shown in Table 1. Minerals, sodium caseinate, milk protein, collagen peptide (trade name; “Marine Matrix” manufactured by Yaizu Suisan Chemical Co., Ltd.), DE25 dextrin, guar gum degradation product, chitin hydrolyzate ( Product name: “NA-COS-Y” manufactured by Yaizu Suisan Chemical Co., Ltd.) and chitosan hydrolyzate (product name: “COS-YS” manufactured by Yaizu Suisan Chemical Co., Ltd.) were stirred and dissolved. Next, succinic acid monoglyceride was dissolved in this oil in advance in a mixed oil of rapeseed oil and medium chain fat, and the mixed oil was added while stirring to perform rough emulsification. Furthermore, vitamins and flavors were mixed and left for 15 minutes with stirring. This crude emulsion was homogenized twice at a homogeneous pressure of 15 MPa and a homogeneous pressure of 50 MPa to obtain an emulsion. 300 ml of this emulsified liquid was filled into a soft bag and subjected to retort sterilization at 122 ° C. for 10 minutes to obtain an emulsified liquid enteral nutrient. The same minerals and vitamins as in Example 1 were used.

[Comparative Example 1]
An emulsified liquid enteral nutrient was obtained according to Example 1 except that chitin (trade name; “PSH” manufactured by Yaizu Suisan Chemical Co., Ltd.) was used instead of the chitin hydrolyzate.

[Comparative Example 2]
An emulsified liquid enteral nutrient was obtained according to Example 1 except that the chitin hydrolyzate was not used and the dextrin of DE25 was changed to 6.3% by mass.

[Comparative Example 3]
An emulsified liquid enteral nutrient was obtained according to Reference Example 4 except that chitosan (trade name; “chitosan PL-90” manufactured by Yaizu Suisan Chemical Co., Ltd.) was used instead of the chitosan hydrolyzate. .

[Comparative Example 4]
An emulsified liquid enteral nutrient was obtained according to Reference Example 4 except that the chitosan hydrolyzate was not used and the DE25 dextrin was changed to 6.1% by mass.

[Comparative Example 5]
An emulsified liquid enteral nutrient was obtained according to Example 7 except that neither chitin hydrolyzate nor chitosan hydrolyzate was used and the dextrin of DE25 was changed to 18.9% by mass.

[Comparative Example 6]
An emulsified liquid enteral nutrient was obtained according to Example 1, except that the amount of chitin hydrolyzate added was 0.55% by mass and the amount of dextrin added was 5.2% by mass.

Immediately after the production of the emulsified liquid enteral nutrients of Examples 1 and 2, Reference Examples 3 to 6, Example 7 and Comparative Examples 1 to 6, and after standing at 20 ° C. for 180 days, pH, viscosity, The average particle diameter and tube fluidity were confirmed, and the results are shown in Table 3.

  The properties are: ◎: no creaming or precipitation and very good dispersion state, ○: no creaming or precipitation and good dispersion state, △: some creaming or precipitation, ×: creaming or precipitation Judgment was made in four stages.

  The pH was measured using a pH meter (trade name: “D-1” manufactured by Horiba, Ltd.).

  Viscosity was measured using a viscometer (trade name: “DV-E” manufactured by Brookfield) at a liquid temperature of 20 ° C.

  The average particle size was measured at a rotational speed of 5,000 rpm using an ultracentrifugal automatic particle size distribution analyzer (trade name; “CAPA-700” manufactured by Horiba, Ltd.).

For tube fluidity, a 6.5 Fr tube was used, and the time required to flow out 200 ml of the emulsion was measured at a drop of 70 cm.

  From the above results, Comparative Example 1 using chitin instead of chitin hydrolyzate, Comparative Example 3 using chitosan instead of chitosan hydrolyzate, and the addition amount of chitin hydrolyzate is 0.5% by mass or more. In the emulsified liquid enteral nutrient of Comparative Example 6, formation of protein aggregates was observed immediately after production. In Comparative Examples 2, 4, and 5 containing no chitin or chitosan hydrolyzate, there was no generation of creaming or precipitation immediately after production and the dispersion state was good, but creaming after storage at 20 ° C. for 180 days, Generation | occurrence | production of the deposit and the aggregate was seen, the increase in average particle diameter and the viscosity raise were recognized.

On the other hand, in Examples 1 and 2, Reference Examples 3 to 6, and Example 7 using chitin hydrolyzate and / or chitosan hydrolyzate in the emulsified liquid enteral nutrient, the generation of creaming, precipitates and aggregates is Further, the viscosity and the average particle diameter were small, and the tube fluidity was good. Furthermore, even when stored at 20 ° C. for 180 days, no creaming, precipitates or agglomerates were generated, the dispersion state was very good, and changes in viscosity and average particle diameter were hardly observed.

Thus, emulsified liquid enteral nutrient of the present invention is excellent in suitability for use as enteral nutrient can simple and stable enteral administration to a patient, and, chitin pressurized hydrolysis Due to the physiological activity effect of the object, it can be expected to improve the joint pain of the patient, prevent the occurrence of wounds and heal.

The emulsified liquid enteral nutrient of the present invention can be used as an enteral nutrient for easily and stably supplying a nutrient solution to the digestive organs such as the stomach and intestine by oral and tube. Further, the physiologically active effects possessed by chitin hydrolyzate, improving therapeutic agent of joint pain, can be used as prevention and healing agents bedsore.

Claims (3)

(A) chitin hydrolyzate containing at least N-acetylglucosamine, (B) protein and / or its degradation product, (C) lipid, (D) saccharide, and (E) emulsifier as main components, total calories in There 70~200kcal / 100ml, relative to the total liquid weight, the 0.01 to 0.5% by weight of (a), said (B) 2.0 to 10.0 wt%, said (C) 1.0-10.0 wt%, the (D) 10 to 30 wt%, wherein (E) 0.05 to 1.0 wt% free with emulsifying liquid enteral nutrient. The chitin hydrolyzate chitin hydrolyzate is bonded 1-8 N- acetylglucosamine molecule according to claim 1 Symbol placement of emulsified liquid enteral nutrient. The chitin hydrolyzate claim 2 Symbol placement of emulsified liquid enteral nutrient is N- acetylglucosamine.